Mereo BioPharma Group plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MREO research report →
About the company
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment.
- CEO
- Denise Vera Scots-Knight
- IPO
- 2019
- Employees
- 36
- HQ
- London, GB
Price Chart
- Market Cap
- $53.42M
- P/E
- -1.49
- P/S
- 106.85
- P/B
- 1.58
- EV/EBITDA
- -0.44
- Div Yield
- 0.00%
- Gross Margin
- -105.73%
- Op Margin
- -7531.06%
- Net Margin
- -7139.75%
- ROE
- -81.25%
- ROIC
- -109.06%
- Revenue
- $500.00K · 0.00%
- Net Income
- $-41,878,000 · 3.18%
- EPS
- $-0.26 · 11.11%
- Op Income
- $-38,257,000
- FCF YoY
- 7.58%
- 52W High
- $3.05
- 52W Low
- $0.20
- 50D MA
- $0.29
- 200D MA
- $0.94
- Beta
- 0.29
- Avg Volume
- 3.43M
Get TickerSpark's AI analysis on MREO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 26, 26 | Jacquet Pierre | other | 106,848 |
| Feb 26, 26 | Jacquet Pierre | other | 66,000 |
| Feb 26, 26 | Yoskowitz Marc J | other | 96,163 |
| Feb 26, 26 | Yoskowitz Marc J | other | 66,000 |
| Feb 26, 26 | Shames Daniel | other | 96,163 |
| Feb 26, 26 | Shames Daniel | other | 66,000 |
| Feb 26, 26 | Ekblom Anders | other | 133,560 |
| Feb 26, 26 | Ekblom Anders | other | 66,000 |
| Feb 26, 26 | Bender Jeremy | other | 117,533 |
| Feb 26, 26 | Bender Jeremy | other | 66,000 |
Our MREO coverage
Recent articles, reports, and earnings notes.
No research on MREO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MREO report →Similar companies
Peers in the same neighborhood.